279 related articles for article (PubMed ID: 21135857)
1. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Witzig TE; Reeder CB; LaPlant BR; Gupta M; Johnston PB; Micallef IN; Porrata LF; Ansell SM; Colgan JP; Jacobsen ED; Ghobrial IM; Habermann TM
Leukemia; 2011 Feb; 25(2):341-7. PubMed ID: 21135857
[TBL] [Abstract][Full Text] [Related]
2. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
Barnes JA; Jacobsen E; Feng Y; Freedman A; Hochberg EP; LaCasce AS; Armand P; Joyce R; Sohani AR; Rodig SJ; Neuberg D; Fisher DC; Abramson JS
Haematologica; 2013 Apr; 98(4):615-9. PubMed ID: 23144193
[TBL] [Abstract][Full Text] [Related]
6. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
Tobinai K; Ogura M; Maruyama D; Uchida T; Uike N; Choi I; Ishizawa K; Itoh K; Ando K; Taniwaki M; Shimada N; Kobayashi K
Int J Hematol; 2010 Nov; 92(4):563-70. PubMed ID: 20972652
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Gertz M; Laplant B; Camoriano J; Hayman S; Lacy M; Chuma S; Harris B; Leduc R; Rourke M; Ansell SM; Deangelo D; Dispenzieri A; Bergsagel L; Reeder C; Anderson KC; Richardson PG; Treon SP; Witzig TE
J Clin Oncol; 2010 Mar; 28(8):1408-14. PubMed ID: 20142598
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
Ghobrial IM; Witzig TE; Gertz M; LaPlant B; Hayman S; Camoriano J; Lacy M; Bergsagel PL; Chuma S; DeAngelo D; Treon SP
Am J Hematol; 2014 Mar; 89(3):237-42. PubMed ID: 24716234
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in diffuse large B-cell lymphomas.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
[TBL] [Abstract][Full Text] [Related]
17. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Younes A; Salles G; Martinelli G; Bociek RG; Barrigon DC; Barca EG; Turgut M; Gerecitano J; Kong O; Pisal CB; Tavorath R; Kim WS
Haematologica; 2017 Dec; 102(12):2104-2112. PubMed ID: 28971900
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Janku F; Park H; Call SG; Madwani K; Oki Y; Subbiah V; Hong DS; Naing A; Velez-Bravo VM; Barnes TG; Hagemeister FB; Falchook GS; Karp DD; Wheler JJ; Piha-Paul SA; Garrido-Laguna I; Shpall EJ; Fayad LE; Neelapu SS; Meric-Bernstam F; Kurzrock R; Fanale MA
Clin Cancer Res; 2020 Nov; 26(21):5579-5587. PubMed ID: 33055173
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P; Barosi G; Rambaldi A; Marchioli R; Masciulli A; Tozzi L; Biamonte F; Bartalucci N; Gattoni E; Lupo ML; Finazzi G; Pancrazzi A; Antonioli E; Susini MC; Pieri L; Malevolti E; Usala E; Occhini U; Grossi A; Caglio S; Paratore S; Bosi A; Barbui T; Vannucchi AM;
Blood; 2011 Aug; 118(8):2069-76. PubMed ID: 21725052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
